Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05717062
Other study ID # OPX-PR-03
Secondary ID FD-R-7830
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 30, 2023
Est. completion date November 2024

Study information

Verified date September 2023
Source Ophirex, Inc.
Contact Brandi Ritter PA-C, MPAS
Phone 5302184454
Email brandi@ophirex.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV varespladib followed by transition to the oral dosage form, varespladib-methyl, concurrently with SOC, in participants bitten by venomous snakes. Note: Funding Source - FDA-OOPD


Description:

This is a multicenter, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of intravenous varespladib followed by oral varespladib, concurrently with standard of care (SOC), in participants bitten by venomous snakes. Approximately 140 male and female eligible participants will be enrolled and randomized to receive active varespladib or placebo (in addition to SOC) Randomization will be stratified by the presence or absence of neurotoxicity (SSS nervous system subscore of 0-1 or ≥ 2) at Baseline, and by receipt of antivenom prior to screening, resulting in 4 strata in total.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date November 2024
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility INCLUSION CRITERIA: 1. Is a male or female = 18 years of age with venomous snakebite. 2. Patients must have known or suspected venomous snakebite. In India, enrollment will be restricted to patients bitten by suspected or confirmed Russell's viper (Daboia russelii) or krait (Bungarus spp.) In the U.S., any snakebite that meets all other criteria may be eligible. 3. Participants must meet one of two categories of inclusion criteria: 1. Category 1: The participant is enrolled within 5 hours of venomous snakebite or symptom onset with an SSS score of =2 in one system and =1 in another system (2+1). OR 2. Category 2: The participant has a suspected or confirmed bite from an elapid and is enrolled within 10 hours of bite or symptom onset with moderate to severe cranial nerve or skeletal muscle weakness. 4. Is willing (or legally authorized representative is willing) to provide informed consent prior to initiation of any study procedures. EXCLUSION CRITERIA: 1. Has history of or is suspected to have CVA or intracranial bleeding of any kind, acute coronary syndrome, MI, or severe pulmonary hypertension. 2. Has known history of inherited bleeding or coagulation disorder. 3. Is, at Screening Visit, using the following anticoagulants: warfarin/coumadin, argatroban, bilvalirudin, lepirudin, apixaban, dabigatran, clopidogrel, prasugrel, ticlodipine or another anticoagulant agent not specifically listed, or has used heparin, enoxaparin, fondaparinux, or other low molecular weight heparin or any antiarrhythmic drugs within 14 days prior to treatment. 4. Has a history of chronic liver disease such as chronic active viral hepatitis, alcohol- related liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis. 5. Reports or has known pre-existing renal impairment or chronic kidney disease. 6. Has a known allergy or significant adverse reaction to varespladib or varespladib-methyl. 7. Is considered by the Investigator to be unable to comply with protocol requirements due to geographic considerations, psychiatric disorders, or other compliance concerns. 8. Is pregnant, has a positive serum human chorionic gonadotropin (hCG) pregnancy test or not willing to use a highly effective method of contraception for 14 days after initial treatment, or is breast-feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Varespladib intravenous form
This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
varespladib-methyl- oral form
Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
Placebo intravenous form
The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
Placebo - oral form
Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina
United States Texas Tech University Health Sciences Center El Paso El Paso Texas
United States Emergency Medicine, University of Kentucky Lexington Kentucky
United States Loma Linda University Medical Center Loma Linda California
United States Desert Regional Medical Center Palm Springs California
United States Banner University Medical Center - Phoenix Phoenix Arizona
United States Antelope Valley Medical Center Rosamond California
United States UT Health San Antonio San Antonio Texas
United States University of South Florida/Tampa General Hospital Tampa Florida
United States Arizona Poison & Drug Information Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Ophirex, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area under the curve of the composite outcome of the pulmonary, cardiovascular, local wound, hematologic, renal and nervous system sections of the snakebite severity score (SSS) from Baseline (pre-dosing) to Day 7. The Snakebite Severity Scale is a tool used to measure the severity of envenoming based on 7 body categories: local wound, pulmonary, cardiovascular, gastrointestinal (graded at levels from Grade 0 to Grade 3), hematological, renal and nervous system effects (graded at levels from Grade 0 to Grade 4).
A higher score indicates worse symptoms. For the primary outcome, 5 body categories (local wound, pulmonary, cardiovascular, hematological, and nervous system) will be included.
Baseline to Day 7
Secondary Area under the curve of the composite outcome of pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the SSS from Baseline to Day 7, among patients receiving study drug, 6 hours after bite or symptom onset The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms. Baseline to Day 7
Secondary Change in the composite outcome of pulmonary, cardiovascular, hematologic, renal, and nervous system sections of the SSS from Baseline to the average of the scores 3 and 6 hours after the first dose. The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms. Baseline to 3 and 6 hours
Secondary Pulmonary, cardiovascular, local wound, hematologic, renal, and nervous system sections of the composite Snakebite Severity Scale from Baseline through Day 7. The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms. Baseline through Day 7
Secondary Elapsed time from initiation IV varespladib treatment until the transition to oral varespladib-methyl. Baseline to Day 28
Secondary Complete Snakebite Severity Scale Scores from baseline to Day 7. The SSS is a tool developed to measure the severity of snakebite envenoming. Each category is graded from 0 to 3 or 4 (depending on the body category) and a higher score indicates worse signs or symptoms. Baseline through Day 7
Secondary Coagulation Abnormalities (subject coagulation lab tests: PT, PTT, fibrinogen, INR will be evaluated) from Baseline through Day 7 Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance. Baseline through Day 7
Secondary Hemolysis markers (subject hemolysis lab tests: free hemoglobin, haptoglobin, LDH will be evaluated) from Baseline through Day 3 Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance. Baseline through Day 3
Secondary Levels of the Myonecrosis Marker, Creatine Kinase (CK) from Baseline through Day 3 Baseline through Day 3
Secondary Kidney function markers (subject lab tests: creatinine, BUN, eGFR will be evaluated) from Baseline through Day 28 Each lab value that is outside of the normal reference range will be evaluated by the investigator to determine clinical relevance. Baseline through Day 28
Secondary Numeric Pain Rating Scale (NPRS) score in patients able to respond pre-dosing through Day 28 The NPRS is an 11-point scale for participants self-reporting of pain with scores ranging from 0 (no pain) to 10 (worst possible pain). Baseline through Day 28
Secondary Total Antivenom Requirement, measured in number of vials of antivenom administered to the subject, from baseline (pre-dosing) through Day 28 Baseline through Day 28
Secondary Head Lift duration (measured time of 0 - 5 seconds of subject's ability to lift head off of the bed, to determine neurological weakness) from Baseline through Day 7 Head lift is used to assess subject for neurological weakness. Baseline through Day 7
Secondary Time from initiation of ventilatory support to initiation of weaning Baseline through Day 28
Secondary Time of ventilatory support from Baseline through Day 28 Baseline through Day 28
Secondary Time of Intensive Care Unit (ICU) Stay from Baseline through Day 28 Baseline through Day 28
Secondary Time of Hospitalization from baseline (pre-dosing) through Day 28 Baseline through Day 28
Secondary All-cause mortality at Day 28 Baseline through Day 28
Secondary Clinical Global Impression - Improvement (CGI-I) from Baseline through Day 28 Clinical Global Impression - Improvement Scale is 0, not assessed, 1 = very much improved to 7 = very much worse Baseline through Day 28
Secondary Patient-Specific Functional Scale (PSFS) total score from Baseline through Day 28 A 3 item instrument administered verbally; 0= unable to perform activity to 10 = able to perform activity at same level as before injury or problem Baseline through Day 28
Secondary Patient Global Impression of Change (PGIC) from Baseline through Day 28 Scale is 1 = no change, to 7= a great deal better Baseline through Day 28
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05872373 - Snakebite Prevention and First Aid Through Community Engagement N/A
Completed NCT03859154 - Waveform Analysis In Snakebite Victims With Hematotoxicity
Enrolling by invitation NCT06124872 - Mapping Snakebite Risk in Kenya and Eswatini
Recruiting NCT04845022 - Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome